Feline hyperthyroidism is the most common endocrine disorder in cats over 10 years, with multiple treatment options offering different welfare profiles and quality of life outcomes for affected animals.
Feline hyperthyroidism welfare management is shaped by the availability of curative treatment — radioactive iodine provides a one-time cure with minimal treatment burden — alongside the daily medication and dietary alternatives suited to cats where radioiodine is impractical. The welfare experience of untreated hyperthyroidism is significant: excessive metabolism causes physical deterioration, cardiovascular stress, and behavioral changes including irritability and hyperactivity that affect quality of life. The concurrent CKD complication requires careful clinical management — treating hyperthyroidism too aggressively can precipitate renal failure. Owner adherence to medication is a welfare-critical factor; cats whose owners struggle with twice-daily pilling may benefit from longer-acting transdermal formulations or dietary management as lower-compliance alternatives.